Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that Swissmedic, the regulatory authority for Switzerland, has granted approval for ABRAXANE® (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) as a treatment for metastatic pancreatic cancer (in combination with gemcitabine), and as a treatment for metastatic breast cancer.ABRAXANE has been approved in more than 30 countries for metastatic pancreatic cancer and over 40 countries for metastatic breast cancer.
No comments:
Post a Comment